ArticleMaterials (Basel, Switzerland)2025
Enhancement of Rheological Performance and Smoke Suppression in Sepiolite-Modified Asphalt.
Article in Materials (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Optimization of Dosage for Asphalt Volatile Harmful Gas Inhibitor Using Multi-Response Satisfaction Function and Nonlinear Regression.Materials (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
To address the technical bottleneck of the coordinated improvement of high-temperature rutting resistance, low-temperature cracking resistance and environmental protection performance of road asphalt, and to address the existing problems in the research of sepiolite modified asphalt, such as the ambiguous microscopic mechanism of action, the lack of quantitative relationship between dosage and performance, and the unclear adaptability of modification processes, this study employed high-purity sepiolite as a modifier. After optimizing its microstructure through organic and surface modification, the sepiolite with the best compatibility with asphalt was selected. Four dosage gradients of 2%, 4%, 6%, and 8% were designed. Rheological tests were conducted to investigate the effects of sepiolite on the rutting resistance at high temperature, the cracking resistance at low temperature, and the fatigue durability of asphalt. Gas chromatography-mass spectrometry (GC-MS) was used to analyze changes in the organic components of asphalt fumes, while Fourier-transform infrared spectroscopy (FTIR) and gel permeation chromatography (GPC) were applied to reveal the microscopic interaction mechanisms and smoke-suppression principles. Results show that pristine sepiolite exhibits the best compatibility with asphalt. Although modified sepiolite shows a 43-45% increase in specific surface area, the overall high-low temperature coordination of the modified asphalt decreases by 10-15%. The sepiolite dosage has a significant influence on asphalt performance: when the dosage is 4-6%, the rutting factor of asphalt increases by 25-30%, indicating the best high-temperature deformation resistance; at 4%, the asphalt creep stiffness decreases by over 15%, minimizing the low-temperature cracking risk; and at 2-4%, the fatigue life extends by 9-13%, with the most notable improvement at 2%. In terms of smoke suppression, the porous structure of sepiolite adsorbs 3-5% of the light volatile components in asphalt, while its metal oxides inhibit the release of aliphatic and aromatic hydrocarbons, reducing toxic fume emissions by 12-18%. Microscopically, the interaction between sepiolite and asphalt is dominated by physical adsorption without chemical functional group recombination. The fibrous network of sepiolite enhances the structural stability of asphalt, while the adsorption of small and medium molecular components optimizes the molecular weight distribution, achieving a dual effect of performance enhancement and smoke suppression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.